Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024

 

 

SAN DIEGO - August 6, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2024, at 4:15 p.m. ET on Wednesday, August 14, 2024.

 

Management will host a conference call on Wednesday, August 14, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

 

Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10191735/fd44630e3d. Please note that registered participants will receive their dial-in number upon registration.

 

Interested parties without internet access or unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

All callers should ask for the Aethlon Medical, Inc. conference call.

 

A replay of the call will be available approximately one hour after the end of the call through September 14, 2024. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 3788019.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Aethlon Medical Inc.

 

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2024/08061AEMD-Q2-Financial-Results-Conferece-Call.asp

 

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

Additional information can be found at www.AethlonMedical.com.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital and to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to submit applications to and obtain approval from the additional Ethics Committees in Australia and India, including on the timing expected by the Company; the Company's ability to initiate its planned oncology clinical trials in Australia and India, including on the timing expected by the Company; the Company's ability to manage and successfully complete its clinical trials, if initiated; the potential impact of Hemopurifier on the H5N1 Avian Influenza (H5N1 HPAI) virus in dairy cattle; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303

 

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Breaking Renewable Energy Stock News: KULR Technology Group (NYSE: $KULR) Sets Second Quarter 2024 Earnings Call for Monday, August 12, 2024 at 4:30 p.m. ET; @KULRTech

Breaking Renewable Energy Stock News: KULR Technology Group (NYSE: $KULR) Sets Second Quarter 2024 Earnings Call for Monday, August 12, 2024 at 4:30 p.m. ET; @KULRTech

 

SAN DIEGO, CA, August 05, 2024 (Investorideas.com Newswire) KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a global leader in sustainable energy management, will hold a conference call on Monday, August 12th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the second quarter ended June 30, 2024. The financial results will be issued in a press release prior to the call.

 

KULR management will host the conference call, followed by a question-and-answer period. Interested parties can submit relevant questions prior to the call to Stuart Smith at SmallCapVoice.Com, Inc. via email: ssmith@smallcapvoice.com by 5:00 p.m. ET on Thursday, August 8th, 2024. Mr. Smith will compile a list of questions and submit them to the Company prior to the conference call. The questions that will get addressed will be based on the relevance to the shareholder base, and the appropriateness of the questions in light of public disclosure rules.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of KULR Technology Group, Inc.

 

Read this news, featuring KULR in full at https://www.investorideas.com/news/2024/08051KULR-Q2-Earnings-Call.asp

 

KULR Technology Group Second Quarter 2024 Earnings Call

Date: Monday, August 12, 2024

Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)

 

To access the call, please register using the following link: KULR Second Quarter 2024 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code and PIN required to join the live call. The conference call will be available for replay here via the Investor Relations section on KULR’s website (www.kulrtechnology.com).

 

About KULR Technology Group, Inc.

KULR Technology Group Inc. (NYSE American: KULR) is a leading energy management platform company offering proven solutions that play a critical role in accelerating the electrification of the circular economy. Leveraging a foundation in developing, manufacturing, and licensing next-generation carbon fiber thermal management technologies for batteries and electronic systems, KULR has evolved its holistic suite of products and services to enable its customers across disciplines to operate with efficiency and sustainability in mind. For more information, please visit www.kulrtechnology.com.

 

Safe Harbor Statement

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. This release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on April 12, 2024, as may be amended or supplemented by other reports we file with the Securities and Exchange Commission from time to time. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely on management’s best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.

 

Investor Relations:

KULR Technology Group, Inc.

Phone: 858-866-8478 x 847

Email: ir@kulrtechnology.com

 

KULR Technology Group, Inc. (NYSE: KULR) is a featured renewable energy stock on Investorideas.com

 

More info on KULR at Investorideas.com Visit: https://www.investorideas.com/CO/KULR/

 

Disclaimer/Disclosure: Disclosure: (NYSE: KULR) is a paid featured company on Investorideas.com effective July 2024 for 3 months. lInvestorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions. More disclosure info can be found here. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Get more Renewable Energy Stock news, articles, podcasts and Stock Directories

 

New Stocks to watch in Tech, Automotive, Biotech and Retail; (Nasdaq: $LCFY) (CSE: $BPAI.CN) (NASDAQ: $FLNC) (NASDAQ: $ZAPP) (NASDAQ: $ZCAR) (Nasdaq: $CRSP) (NYSE: $BDX) (TSX: $ATZ.TO)

New Stocks to watch in Tech, Automotive, Biotech and Retail; (Nasdaq: $LCFY) (CSE: $BPAI.CN) (NASDAQ: $FLNC) (NASDAQ: $ZAPP) (NASDAQ: $ZCAR) (Nasdaq: $CRSP) (NYSE: $BDX) (TSX: $ATZ.TO)

 

 

 

 

August 2, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Tech, Automotive, Biotech and Retail Sectors.

 

The newest automotive stocks are involved in ride-share and 2-wheel EV’s respectively.

 

The latest tech companies use AI for their SEO, Digitasl Marketing and Cleantech solutions, respectively, while the newest biotech companies provide gene therapies and medical technologies.

 

The latest retail company is a Canadian–based luxury brand clothing firm.

 

Read this in full at https://www.investorideas.com/news/2024/main/08021Stocks.asp

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Tech Directories:

Locafy (Nasdaq:LCFY) is a globally recognized software-as-a-service technology company specializing in local search engine marketing. Founded in 2009, Locafy's mission is to revolutionize the US$700 billion SEO sector. We help businesses and brands increase search engine relevance and prominence in a specific proximity using a fast, easy, and automated approach.

 

BrandPilot AI Inc. (CSE: BPAI) the new identity of Xemoto Media Ltd., is headquartered in Toronto, Canada, with a global presence that spans multiple industries. BrandPilot's mission is to help businesses achieve their marketing goals through innovative and data-driven solutions. Through its proprietary technology platform, Spectrum, BrandPilot leverages the power of AI to provide digital marketing and advertising solutions that empower businesses of all sizes to forge enduring connections with their customers.

 

Fluence Energy (NASDAQ:FLNC) is a global market leader in energy storage products and services, and optimization software for renewables and storage. With a presence in 47 markets globally, Fluence Energy, Inc. provides an ecosystem of offerings to drive the clean energy transition, including modular, scalable energy storage products, comprehensive service offerings, and AI-enabled optimization software for managing and optimizing renewables and storage from any provider. The Company is transforming the way we power our world by helping customers create more resilient and sustainable electric grids.

 

New Stocks Added to the Automotive Directories:

Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) and its operating subsidiaries are run by a team of experts from the mobility industry, on a mission to redefine the electric two-wheeler segment. Zapp's debut product, the i300, is an urban electric high-performance two-wheeler capable of traditional motorcycle levels of performance in a step-through format, combining ease of use with exhilaration and fun. The i300 is the first in a suite of high-performance electric two-wheelers that Zapp plans to bring to market. Zapp will offer a high-quality direct-to-customer experience known as DSDTC (drop-ship-direct-to-customer). Customers ordering the i300 online will have their bikes conveniently delivered to their home by authorised “Zappers,” who will provide at-home inspection, service and support throughout the vehicle ownership lifecycle. Zapp is a registered trademark of Zapp Electric Vehicles Limited in the United Kingdom and other countries.

 

Zoomcar Holdings, Inc. (NASDAQ:ZCAR) Founded in 2013 and headquartered in Bengaluru, India, Zoomcar is a marketplace for car sharing focused on emerging markets. The Zoomcar community connects Hosts with guests, who choose from a selection of cars for use at affordable prices, promoting sustainable, smart transportation solutions in growing markets.

 

New Stocks Added to the Biotech Directories:

CRISPR Therapeutics (Nasdaq:CRSP) Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that recently celebrated the historic approval of the first-ever CRISPR-based therapy and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY™ (exagamglogene autotemcel) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom.

 

Becton, Dickinson and Company (NYSE:BDX) BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. 

 

New Stocks Added to the Retail Directories:

Aritzia Inc. (TSX: ATZ) is a design house with an innovative global platform. We are creators and purveyors of Everyday Luxury, home to an extensive portfolio of exclusive brands for every function and individual aesthetic. We're about good design, quality materials and timeless style — all with the wellbeing of our People and Planet in mind.

Founded in 1984 in Vancouver, Canada, we pride ourselves on creating immersive, highly personalized shopping experiences at aritzia.com and in our 115+ boutiques throughout North America — for everyone, everywhere.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

 

 

Biotech Stocks in Focus (NYSE American: $NNVC) (NYSE: $PFE) (NYSE: $GSK) (NASDAQ: $MRNA)

 

Biotech Stocks in Focus (NYSE American: $NNVC) (NYSE: $PFE) (NYSE: $GSK) (NASDAQ: $MRNA)

 

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

 

August 2, 2024 - Investorideas.com, a go-to investing platform covering biotech and nanotechnology issues a snapshot looking at news and developments in the antiviral market, featuring NanoViricides, Inc. (NYSE American: NNVC), a development stage company that is creating special purpose nanomaterials for antiviral therapy. 

 

From COVID to RSV and now Bird Flu, the global threat of viruses is only a headline away and there is a lot of profit for companies offering solutions. 

 

The Global Antiviral Drugs Market is estimated to reach USD 74.75 Bn by 2028, says Research and Markets and nanotech companies are aiming for a big piece of that pie.

 

Talking about nanotech’s future role in the antiviral market, a recent article in Nature says,  “Nanotechnology with precise control over the properties and structures of nanomaterials holds tremendous potential in the field of antiviral applications. The application of nanotechnology in the antiviral field, including the efficient delivery of antiviral drugs, the blocking of viral infections, and the activation of immune responses, offers new strategies and approaches, bringing renewed hope for infectious disease treatment and prevention.”

 

According to a recently released report from Zacks Small Cap Research, “NanoViricides (NYSE American: NNVC) Broad Spectrum Technology Represents Potential Paradigm Shift in Viral Therapy.”

 

Continued: “NanoViricides is a biopharmaceutical company developing anti-viral therapeutics based on its proprietary nanoviricide technology. A Phase 1 safety study of the company’s lead asset, NV-387, was recently completed and we anticipate results from the study being available in the second half of 2024. A Phase 2 clinical trial in Respiratory Syncytial Virus (RSV) is currently being planned. As opposed to currently available antiviral therapies in which each compound is only active against a unique type of virus, NanoViricides has disclosed preclinical results for NV-387 in multiple viral models that demonstrates the broad-spectrum action of the compound. These results could represent a new paradigm in viral therapy.”

 

Paid news dissemination on behalf of NanoViricides

 

Read this news, featuring NNVC in full at https://www.investorideas.com/news/2024/nanotech/08021Better-Solutions-for-Viruses.asp

 

On July 24^th NanoViricides issued a reminder on the strong safety and effectiveness against coronaviruses demonstrated by its lead clinical drug candidate NV-387.

 

"President Joe Biden has thankfully recovered from the bout of COVID caused by a new variant," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "This again brings into limelight the lack of strong drugs against COVID; a gap that NV-387 is expected to fulfill." 

 

From the news: There is clearly a need for a highly effective and preferably oral drug against COVID. COVID in the USA has become a biannual affair, with ever new, different variants leading each new wave. COVID continues to claim annually greater numbers of lives and hospitalizations than Influenza.

 

We believe it is important to bring to the attention of everyone how strong the activity of NV-387 in animal studies against coronaviruses has been, even compared with the most effective anti-coronavirus drug, namely, remdesivir (Veklury® Gilead).

 

We have studied a lethal lung infection in rats with a coronavirus that results in the same pathology but only milder than the delta variant, in humans as compared to COVID.

 

In one study, NV-387 intravenous injection (I.V.) treatment led to a substantial improvement in survival, of 180%, as compared to Remdesivir  (Pfizer Inc. NYSE:PFE), of only 50%.

 

Continued: We thereafter developed an oral formulation of NV-387 and studied its effect in comparison to the NV-387 I.V. treatment.

 

The results indicate that NV-387 oral drug is expected to be highly effective in treatment of COVID infections. The results also suggest that for hospitalized patients, NV-387 injectable form would be preferable over the oral form.

 

The focus throughout the pandemic has been primarily on antibodies and vaccines. Antibodies as drugs are now clearly evidenced to be not useful for a long enough period to provide major public health benefits. The limits of vaccines and vaccination campaigns both have also become clearly evident. In this scenario, Paxlovid™ (Pfizer Inc. NYSE:PFE),  remains the only oral drug available, in spite of its known weak clinical effectiveness, which is evidenced in clinical trials that showed that in otherwise healthy adults it was not shown to be better than placebo.

 

Additional drug development for COVID treatment is clearly a public health necessity. NV-387 is possibly the most advanced drug candidate that has demonstrated both strong activity and safety in a number of studies towards regulatory approvals.

 

NV-387 has undergone Phase I human clinical trial to evaluate the safety and tolerability in the form of two different oral formulations, namely, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies in India. There were no dropouts and there were no reported adverse events, indicating excellent safety and tolerability of NV-387 even at high dosage levels.

 

We have also found that NV-387 has a very wide antiviral spectrum, covering at least the following: Coronaviruses, RSV, Influenza, and Poxviruses (Smallpox/Mpox). This indicates that antiviral drug resistance against NV-387 would be highly unlikely.

 

Reporting on Pfizer’s (NYSE:PFE) Paxlovid™, Reuters recently noted, “A 15-day course of Pfizer's (PFE.N), opens new tab COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers.”

 

Continued: Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection.

 

Scientists and patients had hoped that Pfizer's two-drug oral treatment would ease symptoms of long COVID after anecdotal reports of patients who said Paxlovid helped them.

 

Continued: But the15-week, 155-participant study failed to show that a 15-day course helped more than a placebo in reducing fatigue, brain fog, shortness of breath, body aches, or gastrointestinal or cardiovascular symptoms. Trial participants, on average, had been sick more than 16 months before enrolling in the trial.

 

"We did not see a measurable difference based on patient reported outcomes in the six composite symptoms together," Stanford Medicine Professor, Dr. Upinder Singh said in an interview. "We didn't see a benefit in individual symptoms either."

 

The vaccine market is shifting after companies were making record profits during COVID, but there is still big money at play and new viruses to address. 

 

FiercePharma reported, “GSK (NYSE: GSK) reported sales of 1.24 billion euros ($1.53 billion) in the third and fourth quarter for its RSV shot Arexvy, which is for people ages 60 and older. Meanwhile, Sanofi and AZ-partnered pediatric shot Beyfortus generated 547 million euros ($592 million) in sales, a figure expected to double in 2024.”

 

Continued: “Industry experts who we’ve spoken to believe the global market opportunity for RSV vaccines is substantial, possibly reaching ($9 billion to $10 billion) and supporting attractive growth for leading companies,” Third Bridge’s Brown noted.

 

Zacks Equity Research looking at the biotech sector earlier this week, commented on Moderna, Inc. (NASDAQ:MRNA), once the darling of the COVID era, noting it is diversifying its pipeline. “Moderna recently obtained a significant boost with the FDA approval of RSV vaccine mResvia to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) in older adults aged 60 years and above. The vaccine is scheduled for commercial launch during the 2024 fall season.

 

The company plans to launch several new marketed products over the next five years. With these potential launches, management aims to not only boost its revenues but also reduce dependence on Spikevax. As one of the first-ever COVID-19 vaccine makers, Moderna’s robust product sales boosted cash resources and enabled it to accelerate its pipeline development. The company is developing cytomegalovirus, cancer and influenza vaccines in late-stage studies.”

 

Vaccines are not the only answer to virus treatment, so  big pharma will be looking to innovate to capture market share and new opportunities.

 

NanoViricides, Inc. (NYSE American: NNVC) said in its most recent news, “We are now seeking collaborations with Pharma companies to bring this remarkable drug, NV-387, towards regulatory approvals for multiple antiviral indications.”

 

NanoViricides stated earlier in July, “We are living in a world with many viruses that threaten our health. The current model of developing a drug against each virus separately is expensive and untenable with the myriad of viruses affecting humans that are gaining major foothold.”

 

“NV-387 turns this drug development model on its head, with a single drug that would be effective against many of these viruses. It simplifies preparedness for pandemics. It reduces cost of development to a single drug instance.”

 

Research and find more biotech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

 

Research Nanotech stocks at Investorideas

https://www.investorideas.com/Nanotechnology/Stocks_List.asp

About Investorideas.com

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.

 

Disclaimer/Disclosure: This news article featuring NanoViricides, Inc. (NYSE American: NNVC)  is a paid for news release creation and dissemination on Investorideas.com.  Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Nanotech Stocks- investing ideas in nanotechnology stocks,

Get more Nanotech news, articles, and stock directories